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Clostridium difficile is an anaerobic, Gram-positive, and spore-forming bacterium that is the leading worldwide infective cause
of hospital-acquired and antibiotic-associated diarrhea. Several studies have reported associations between humoral immunity
and the clinical course of C. difficile infection (CDI). Host humoral immune responses are determined using conventional en-
zyme-linked immunosorbent assay (ELISA) techniques. Herein, we report the first use of a novel protein microarray assay to
determine systemic IgG antibody responses against a panel of highly purified C. difficile-specific antigens, including native tox-
ins A and B (TcdA and TcdB, respectively), recombinant fragments of toxins A and B (TxA4 and TxB4, respectively), ribotype-
specific surface layer proteins (SLPs; 001, 002, 027), and control proteins (tetanus toxoid and Candida albicans). Microarrays
were probed with sera from a total of 327 individuals with CDI, cystic fibrosis without diarrhea, and healthy controls. For all
antigens, precision profiles demonstrated<10% coefficient of variation (CV). Significant correlation was observed betweenmi-
croarray and ELISA in the quantification of antitoxin A and antitoxin B IgG. These results indicate that microarray is a suitable
assay for defining humoral immune responses to C. difficile protein antigens and may have potential advantages in throughput,
convenience, and cost.
Clostridium difficile is the leading worldwide infective cause ofhospital-acquired and antibiotic-associated diarrhea, impos-
ing a considerable financial burden on health service providers in
both Europe and the United States (1–3). Infection causes a spec-
trum of clinical presentations ranging from an asymptomatic car-
rier state to severe fulminant colitis and death (4). Following suc-
cessful treatment, an estimated 20% to 30% of patients with
primary C. difficile infection (CDI) develop recurrence of symp-
toms, caused by either relapse of the original infection or reinfec-
tion with a new strain (5).
This anaerobic and spore-forming bacterium exerts its major
pathological effects through two proinflammatory and cytotoxic
protein exotoxins, TcdA (toxin A) and TcdB (toxin B) (6). Non-
toxin virulence factors, such as surface layer proteins (SLPs) and
cell wall proteins, have also been described and may play a role in
disease expression (7–9).
The majority of healthy adults have detectable antibodies to C.
difficile TcdA and TcdB in their sera that are thought to arise from
colonization in infancy or from repeated exposure toC. difficile in
adulthood from the environment (10, 11). Several clinical studies
suggest that adaptive humoral immune responses, in particular to
TcdA and TcdB, may influence clinical outcomes of CDI (12).
Most notably, a landmark study in 2000 reported that a low IgG
titer to TcdA, but not TcdB, at the time of infection is associated
with development of symptomatic disease (13).More recently, the
same group demonstrated an association between median IgG
titers to TcdA and 30-day all-cause mortality (14). Several reports
have also assessed antibody responses following infection and
have shown protection against recurrence associated with anti-
body responses to TcdA, TcdB, and several nontoxin antigens
(Cwp66, Cwp84, FliC, FliD, and the surface layer proteins) (15–
18). In contrast, other studies have reported that humoral im-
mune responses did not influence the clinical course of CDI (18–
21). These conflicting reports may be attributed to heterogeneity
in study design and subject populations. Although the role of hu-
moral immunity remains incompletely understood, vaccination
strategies using inactivated toxins or recombinant toxin frag-
ments are currently the subject of intense investigation (22, 23).
More recently, the possibility of adding other vaccine targets, such
as surface-associated proteins and polysaccharides, to toxin com-
binations is gaining traction and could be of added value in the
prevention of C. difficile colonization and disease transmission
(22, 23). It is likely that the design of these next-generation mul-
ticomponent vaccines targeting colonization, persistence, and
toxin production will stimulate the requirement for evaluating
humoral immune responses to multiple antigens.
The enzyme-linked immunosorbent assay (ELISA) is the tra-
ditional method of accurately quantifying antibodies with differ-
ent specificities in epidemiologic research and vaccine develop-
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ment as well as in the diagnosis of allergies and autoimmune and
infectious diseases. We and other groups (13, 15, 18–20) have
independently developed and used a traditional standardized
ELISA format for the purposes of determining human specific IgG
responses against C. difficile antigens (toxins). However, ELISA-
based tests can be time consuming and require large quantities of
both sample and reagents, thus limiting their potential for high-
throughput use (23, 24). ELISA offers only monoplex data, or
results of a single protein per assay (typically TcdA, TcdB, or SLPs)
and from a single C. difficile strain. Additional concerns include
the lack of a uniform standard for calibration purposes and, thus,
no generally accepted way of expressing ELISA units as well as
poor consistency between protocols and reagents, including, no-
tably, the quality and source of antigens. Moreover, the linear
region of the dynamic range is highly platform dependent.
Recently, protein microarrays, a miniaturized version of a
sandwich ELISA, have evolved as a promising tool for quantifying
specific antibodies directed against various microbial antigens in
human sera, and they may be an attractive alternative to conven-
tional ELISA in determining antigen-specific antibody responses
(25–31).Microarray assays have potentially important advantages
compared with standard ELISA formats. These include a much
increased capacity formultiplexing detection of a range of specific
antibodies due to the flexibility of array printing of multiple anti-
gens per array over a single protein; vastly reduced requirements
for antigens, serum, and reagents; increased assay robustness due
to increased technical replication within each assay; multiple in-
ternal quality control measures; and improved quality control ca-
pabilities. The unique capabilities of microarray, including paral-
lelism, high-throughput, andminiaturization, are ideally suited to
comprehensive investigation of the humoral immune response to
the entire proteome of an infectious agent consisting of thousands
of potential antigens in a patient-specific manner (29). Microar-
ray technology can also be applied to the development of im-
proved serodiagnostic tests, discovery of subunit vaccine antigen
candidates, epidemiological research, and vaccine development,
in addition to providing novel insights into infectious disease and
the immune system (29).
We have developed and validated a novel customizedmicroar-
ray platform that enables the simultaneous quantification of sys-
temic IgG immune responses to a 7-plex panel of highly purified
C. difficile-specific virulence factors, including whole toxins A and
B, recombinant fragments of toxin A (TxA4) and toxin B (TxB4),
ribotype-specific surface layer proteins, and suitable control pro-
teins.We compared the performance of themicroarray technique
with a conventional ELISA using an established panel of sera.
MATERIALS AND METHODS
Microbial proteins and serum samples. Highly purified whole toxins A
and B (toxinotype 0, strain VPI 10463, ribotype 087) in addition to re-
combinant toxin fragments TxA4 and TxB4 (comprising central and re-
ceptor binding domains and both based on toxinotype 0 sequences) were
obtained from Public Health England, United Kingdom (provided by
Clifford Shone). Purified PCR ribotype-specific native whole SLPs (001,
002, 027) were provided by Dublin City University, Eire (provided by
Christine Loscher). Positive controls incorporated on each plate included
tetanus toxoid and lysates from Candida albicans containing the cyto-
plasm and cell wall. Negative controls included spotted printing buffer
(phosphate-buffered saline [PBS] Trehalose Tween) and no serum
(blank) on each array.
Banked sera from adult patients with CDI (n  150; median age, 67
years [range, 19 to 98 years]), a group of patients with cystic fibrosis (CF)
without diarrhea (n  17, 2 of which patients were found to be asymp-
tomatic carriers; median age, 28 years [range,19 to 49 years]), and healthy
controls (n 67; median age, 36 years [range, 22 to 65 years]) were used
to investigate the ability of the microarray assay to detect the presence or
absence of IgG directed againstC. difficilemicrobial and control antigens.
Adult healthy donors were recruited fromwithin the hospital and univer-
sity workforce setting. All the patients in the CDI group had diarrhea
(defined as a change in bowel habit with 3 or more unformed stools per
day for at least 48 h) and positive stoolC. difficile toxin test. Asymptomatic
carriers were defined as thosewho did not have diarrhea but had a positive
stool culture forC. difficile. The diagnosis of CF had previously beenmade
on the basis of a positive sweat test and/or demonstration of 2 known CF
mutations and typical clinical features of disease (without a history of
CDI). All subjects provided written informed consent under approvals
granted by the Nottingham Research Ethics Committee.
Preparation and processing of arrayed antigens.Microbial antigens
were diluted to 200 g/ml in printing buffer (PBS Trehalose Tween) in a
384-well plate (Genetix) and spotted in quadruplicate in a 16 16 array
format onto poly-L-lysine-coated glass slides (Electron Microscopy Sci-
ences) using a BioRoboticsMicroGrid II arrayer (MicroGrid 610, Digilab,
Malborough, MA, USA) in addition to 15 human serial IgG dilutions
(range, 50 g/ml to 3.05 ng/ml) to create a calibration curve. The slides
were blocked with 5% bovine serum albumin (BSA) diluted in PBS-
Tween (PBST; PBS containing 0.05% Tween 20) wash buffer for 1 h at
room temperaturewith shaking. Afterwashing 5 times for 3min eachwith
PBST, all slides were incubated with sera diluted 1:500 in antibody diluent
(Dako) for 1 h. Following washing, the slides were incubated with biotin-
ylated antihuman IgG (Vector Laboratories) diluted 1:20,000 in antibody
diluent for 1 h. After further washing, slides were incubated with Strepta-
vidinCy5 (eBioscience) diluted 1:2,000 in 5%BSA for 15min. After a final
wash with PBST followed by distilled water, slides were dried by centrif-
ugation at 500 g for 4min.Unless stated otherwise, all wash steps were
carried out at room temperature with shaking. Slides were scanned
using a GenePix 4200AL scanner, a photomultiplier tube with 450 nm,
and 100% power. The resultant tagged image file format (TIFF) images
were processed with Axon Genepix Pro-6 microarray image analysis
software (Molecular Services, Inc.) to obtain fluorescence data for each
feature and generate GenePix results format (gpr) files. Protein signals
were finally determined with background subtraction using the
RPPanalyzer, a module within the R statistical language on CRAN
(http://cran.r-project.org/) (32).
Statistical analysis. Antibody levels were calculated using GraphPad
Prism 6.0 software. As data collected for antibodymeasurements were not
normally distributed, nonparametric tests were employed, with medians
and ranges calculated. For the comparison of multiple groups, the
Kruskal-Wallis one-way analysis of variance was used with Dunn’s post-
test. Correlation was evaluated using the Spearman rank correlation co-
efficient test. P values of 0.05 were considered to represent statistically
significant differences.
RESULTS
Quality control measures. Internal quality control (QC) mea-
sures on each array were devised to support interassay normaliza-
tion, assay performance, and data acquisition machine perfor-
mance monitoring. These measures included the addition of a
replicated serial dilution of human IgG to verify the function of
the detection system and provide a standard curve of human IgG
against which antibody responses could be calibrated. Antigens
from 2 known human pathogens (tetanus toxoid and Candida
albicans), of which the majority of normal individuals would be
expected to have some existing protective antibody response, were
incorporated onto each array. These positive-control antigens
were examined for each array as an indicator of sample integrity.
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Figure 1 shows a plot of the responses seen in 327 serum samples
for each of the 2 control antigens. Strong responses are seen to
tetanus toxoid and Candida albicans. Negative controls were also
incorporated onto each array as a further internal QC measure.
Microarray intraassay and interassay precision. Microarray
intraassay and interassay variabilities were calculated using the
sera of 7 patients. Identical samples were assayed on each of 2
slides at 2 independent time points. All antigens were spotted in
replicates of 5 on each array. In the case of intraassay variation, all
7 test and 2 control antigens fell within acceptable limits of preci-
sion (coefficient of variation [CV]10%) (toxin A, 7.76%; toxin
B, 6.39%; SLP001, 7.44%; SLP002, 5.19%; SLP027, 7.64%; TxA4,
7.03%; TxB4, 3.71%; tetanus, 4.21%; Candida albicans, 8.28%).
The interassay coefficient of variation for each antigen was calcu-
lated as 7.76%, 6.39%, 7.44%, 5.19%, 7.64%, 7.03%, 3.71%,
4.21%, and 8.26%, respectively.
Correlation between microarray and ELISA results. Due to
the lack of validated and commercially available quantitative and
standardized IgG ELISAs targeting toxins A and B or other C.
difficile-associated antigens, we compared specific IgG antitoxin A
and antitoxin B antibody measurements generated by microarray
versus previously obtained in-house indirect ELISA readings us-
ing the same patient test sera (21). The Spearman correlation co-
efficient was used to assess the level of agreement between the two
platforms, and results are visually represented in Fig. 2. When
comparing the microarray performance with the in-house
ELISAs, a good correlation coefficient was observed for toxin A
(r 0.7051; P 0.0001), with a moderately good correlation for
toxin B (r 0.5809; P 0.0001).
Sensitivity and specificity. Sensitivity and specificity of indi-
vidual and panels of antibody response to C. difficile-specific an-
tigens were calculated for both the CDI and CF groups using se-
lected age-matched samples and the same panel of 7 antigens
(toxin A, toxin B, SLP001, SLP002, SLP027, TxA4, and TxB4)
based upon the same cutoff 95th percentile of the control samples.
CF samples had a sensitivity and specificity of 75% and 100%,
respectively, while the sensitivity and specificity for CDIwere 25%
and 100%, respectively.
Serum antibody reactivity profiles using microarray. A total
of 327 serum samples were tested by microarray for the presence
of specific IgG antibody. The microarray assay was able to detect
specific antibody responses to all C. difficile antigens, including
recombinant toxin fragments tested (example response to native
antigens demonstrated in Fig. 3). The signals from positive-con-
trol proteins (tetanus toxoid andCandida albicans)were similar in
healthy control individuals, patients with CF, and patients with
CDI. Each array also included negative controls (buffer only and
no serum or blank) which gave no signal. The reactivity of these
spots was routinely subtracted from all signals obtained from spe-
cific antigens. The microarrays detected significantly higher levels
of specific antibodies in the CF group across allC. difficile antigens
tested compared with healthy controls and with CDI sera (Fig. 4).
In the CDI group, antibody responses to whole (Fig. 4A and B)
and recombinant toxins A and B (Fig. 5) did not differ compared
with the healthy control group, but infected patients did exhibit
significantly lower anti-SLP IgG levels (all ribotypes) compared
with controls and with patients with CF (Fig. 4C). No statistically
significant differences were observed in specific antibody levels to
any of the antigens comparing single and relapsing CDI sera (data
not presented).
DISCUSSION
Current knowledge of the complete antigen repertoire recognized
by patients during CDI is sparse, limiting a detailed interrogation
FIG 1 Testing sample integrity of all serum samples using two positive-control antigens: tetanus toxoid andCandida albicans antigen. Strong responses are seen
to both antigens from all the samples.
FIG 2 Correlation between microarray and enzyme-linked immunosorbent assay (ELISA) IgG anti-toxin A (A) and IgG anti-toxin B (B) antibody levels in
patients withC. difficile infection and in patients with cystic fibrosis without a history of diarrhea. Each dot represents a serum sample from an individual patient.
Spearman correlation coefficient tests revealed significant agreement between both assay results.
Clostridium difﬁcile Antigen-Speciﬁc Microarrays
September 2015 Volume 22 Number 9 cvi.asm.org 1035Clinical and Vaccine Immunology
 o
n
 O
ctober 5, 2015 by Univ of Nottingham
http://cvi.asm
.org/
D
ow
nloaded from
 
of immunity and exposure and hindering preclinical vaccine de-
velopment. The goal of this study was to develop, validate, and
implement a novel protein microarray readout assay that allows
the accurate, precise, and reproducible quantification of specific
antibody responses to a selected panel of C. difficile-specific mi-
crobial antigens using a preexisting bank of test sera.
This study represents, to our knowledge, the first report of
highly purified anti-SLP 001, 002, and 027 IgG responses in a large
cohort of patient sera and extends the usefulness of immunoassay
techniques through simultaneous examination of multiple C. dif-
ficile-specific antigens, including toxins in one immunoassay lay-
out. We demonstrate that serum C. difficile antigen-specific IgG
antibody responses can be detected using this technique and that
the magnitude and breadth of response to individual specific mi-
crobial antigens differ greatly between individuals and patient
groups.
While our assay achieved excellent specificity for the target
panel of antigens analyzed, lower detection sensitivity was ob-
FIG 3 Selected serum IgG responses to C. difficile proteins on microarray. Green (low) to red (high) signal intensity heat map representing the relative IgG
response toC. difficile immunoreactive antigens (native toxins A andB and ribotype-specific surface layer proteins 001, 002, 027) in different serum samples from
patients infected with C. difficile, CF patients, and healthy controls.
FIG 4 Anti-toxin A (A) and anti-toxin B (B) IgG responses in healthy controls, in patients with C. difficile infection, and in a group of patients with cystic
fibrosis and no history of diarrhea. Differences between groups were calculated using the Kruskall-Wallis test followed by Dunn’s posttest for multiple
comparisons. Horizontal lines in each graph represent the median. (C) Patients with cystic fibrosis had significantly higher levels of specific IgG antibody
levels to toxins A and B compared to healthy controls and patients with C. difficile infection. In the microarray assays, there were significantly lower
anti-surface layer protein (SLP) IgG levels across all ribotypes tested (001, 002, 027) in patients with C. difficile infection compared to patients with cystic
fibrosis and healthy controls (P values of ***,0.001; **,0.01; *,0.05).
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served, particularly for the CDI group. Importantly, antibody-
based serological assays are hampered by the high likelihood or
prior exposure to microorganisms encountered in the environ-
ment. In this regard, all populations previously exposed to C. dif-
ficile bacterial antigens will produce seropositive responses. Nev-
ertheless, it should be possible to enhance sensitivity for specific
antibody detection through probing the microarrays with a larger
bank of longitudinal (acute and convalescent) test sera and/or
activated B lymphocyte supernatant samples, which secrete anti-
gen-specific antibodies from patients with symptomatic CDI (21)
and healthy controls who do not carry C. difficile in their stool. In
addition, detection sensitivitymay be improved by pooling several
antigenic targets specific for C. difficile.
In contrast to previous studies asserting that development of
symptomatic CDImay be correlated with low IgG titers to toxin A
but not to toxin B, our data do not demonstrate any significant
differences in IgG antitoxin A or IgG antitoxin B levels in CDI
patients compared to healthy controls. Similarly, other investiga-
tors have either reported no disparities or higher serum antitoxin
A IgG levels in CDI patients compared to controls (11, 19, 33).
Although the carriage rate ofC. difficile in the control subjects was
not known, the lack of difference may have arisen due to the fact
that most of the healthy control subjects in this study were re-
cruited from a pool of hospital and university coworkers. As such,
it is likely that natural asymptomatic exposure to toxigenic C.
difficile was a more common occurrence and, thus, may be due to
transient colonization. Furthermore, we acknowledge that pa-
tients in the CDI groupwere also older compared to individuals in
the CF and control groups. However, other investigators have
shown that serumantibody levelswere not affected by age (13, 15).
It will be of interest to determine whether specific qualitative and
quantitative differences in T and B cell responses toC. difficile and
its antigens account for a higher prevalence of CDI in older pop-
ulations.
Notably, significantly higher antitoxin and anti-SLP IgG anti-
body concentrations in patients with CF (with no history of CDI)
are likely to be due to more frequent contact with the toxins and
SLPs of C. difficile which occur with colonization (especially after
admission to hospital) and following antibiotic-mediated disrup-
tion of the protective residentmicroflora. Indeed, 2 of the patients
with CF were asymptomatic carriers of C. difficile. Furthermore,
this particular small cohort of CF patients also had additional risk
factors for C. difficile colonization/infection, including tube feed-
ing (n 5) and the use of proton pump inhibitors (n 14).
While firm conclusions cannot be drawn because of the small
number of subjects studied, our present data suggest that the
host’s ability to mount a robust antibody response to multiple C.
difficile-specific protein antigens, as seen in the CF group, may
help confer protection from developing symptomatic CDI. Pro-
tection from symptomatic CDI may be a higher-order phenome-
non related to patterns of antibody response as opposed to being
attributable to any single antigenic target. Notably, CDI is rarely
seen in CF patients despite the presence ofmultiple risk factors for
infection, including frequent exposures to antibiotics and hospi-
tals. Several studies have also shown that patients with CF are
often asymptomatic carriers ofC. difficile (34–37), with one recent
report indicating that most strains carried by CF patients were
nontoxigenic (77% versus 17%) (37). It is also possible that colo-
nization with nontoxigenic C. difficilemay protect against coloni-
zation with toxin-producing strains and/or that the differences in
colonic mucus or the microbiome may also contribute to protec-
tion in the CF population. Understanding the role of the gut mi-
crobiota in programming the immune phenotype in the context
of CF may offer a series of interactive windows that could be
aligned to prevent CDI. Further detailed studies that aim to dissect
the complex dialogue among the host, immune system, and intes-
tinal microbiota are under way in a larger cohort of CF patients.
Limitations of the present study are the small sample of strain-
specific bacterial proteins employed, unequal sample sizes in the
different groups studies, lack of age matching, the absence of col-
onizing/immunizing strain information, the study of only one
isotype, the lack of antibody neutralization data, and the absence
of ELISA and microarray correlation data for the recombinant
toxin fragments and nontoxin antigens examined.Whether or not
the immunogenicity of the recombinant toxin fragments and
nontoxin antigens contributes to CDI protection remains to be
fully determined. We observed a lower correlation between mi-
croarray and ELISA in the toxin B assays (r 0.58; P 0.0001).
This finding was particularly apparent at increasing IgG antitoxin
B concentrations and may mean that ELISA lacks accuracy at
higher specific antitoxin B IgG concentrations. Discordance be-
tween bothmethods could also be an effect of the low throughput
of ELISA that requires the samples to be analyzed in small batches
over a longer period of time; by contrast, the high-throughput
array platforms permit analysis of large sample cohorts under sim-
ilar experimental conditions in a much more rapid time frame,
FIG 5 Anti-TxA4 (A) and anti-TxB4 (B) IgG responses in healthy controls, in
patients withC. difficile infection, and in aCF group of patients with no history
of diarrhea. Differences between groups were calculated using the Kruskall-
Wallis test followed by Dunn’s posttest for multiple comparisons. Horizontal
lines in each graph represent themedian. In themicroarray assays, CF patients
displayed significantly higher IgG levels against both recombinant toxin frag-
ments compared to healthy controls and patients with C. difficile infection
(***, P 0.001).
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likely enhancing result reproducibility. Discrepancies between
both technologies may also have arisen due to variations in the
quality of sera and toxins over time, especially when new batches/
different sources of toxin were tested. These results also suggest
that mapping temporal changes in serological responses to C. dif-
ficile may be best undertaken using high-throughput methods,
such as protein microarray.
In summary, we verify that this initial design and implementa-
tion of a protein microarray platform is well suited to identify,
quantify, and compare multiple specific antigenic responses fol-
lowing challenge by C. difficile. Given that antigenic variation oc-
curs between different strains, host responses may well vary ac-
cording to which are the prevalent strains. High-throughput
assays will be important in measuring the heterogeneity of host
immune responses. Modifications of this microarray approach
could be employed to expand the antigen targets to include pro-
teins derived from multiple strains of C. difficile in addition to
investigating multiple isotype specificities. The microarray plat-
form could also be adapted to study cytokine/chemokine reper-
toires in response to infection or vaccination for large collections
of individual patient sera. Optimized immunologicalmarker pan-
els are yet to be developed for predicting host responses to C.
difficile. Before advancements can be made, more detailed careful
studies in larger, well-defined prospective cohorts will be required
before this C. difficile antigen-specific microarray assay can be
used as a prognostic tool as well as for tailoring interventional
strategies. Nevertheless, protein microarrays have the potential to
provide a more comprehensive, antigen-specific, humoral im-
mune response profile in vaccinated or infected humans that
could find beneficial applications in large-scale seroepidemiologi-
cal, longitudinal, and serosurveillance analyses.
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